Loading patent…
AssigneeObschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises”
InventorsVladimir Evgenievich Nebolsin, Andrei Yurievich Egorov
Estimating the term…
The invention relates to medicine, in particular, to a method for preventing and/or treating a disease associated with a reduced density of interferon receptors, the method comprising administering an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof. Said disease may be hepatitis B, herpes, papilloma virus infection, or multiple sclerosis. The invention also relates to a pharmaceutical composition for prevention and/or treatment of diseases associated with a reduced density of interferon receptors, wherein the composition comprises an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof. The invention solves a problem of providing a novel agent effective for overcoming a resistance to interferon therapy in diseases selected from the group including hepatitis B, herpes, papilloma virus infection, or multiple sclerosis.
A method for preventing and/or treating a disease associated with a reduced density of interferon receptors, the method comprising administering an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof.
A method for preventing and/or treating a disease selected from the group including hepatitis B, herpes, papilloma virus infection, and multiple sclerosis, the method comprising administering an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition for prevention and/or treatment of a disease associated with a reduced density of interferon receptors, the composition comprising an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.